@ibdnaik @fudmanMD @MondayNightIBD I believe there’s a lot of interest in Tofa to be used as steroid sparing induction strategy w transition to a maintenance agent like Vedo @ibdnaik ! Thoughts ? #MondayNightIBD @IBD_Houston @NMH_SHanauerMD @RPanaccione
Tofacitinib is a molecule inhibitor of JAK for the treatment of ulcerative colitis. Stephen Hanauer, MD, and colleagues evaluated the onset of symptom improvement in post-hoc analyses of data from phase 3 trials of induction therapy with tofacitinib. htt
Stephen Hanauer, MD, and colleagues evaluated the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy with tofacitinib in patients with UC (OCTAVE Induction 1 and 2). Read more about their findings: https:/
RT @NMGastro: Stephen Hanauer, MD and physicians in the #gastroenterology field evaluated the onset of symptom improvement in post-hoc anal…
RT @NMGastro: Stephen Hanauer, MD and physicians in the #gastroenterology field evaluated the onset of symptom improvement in post-hoc anal…
Stephen Hanauer, MD and physicians in the #gastroenterology field evaluated the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy with tofacitinib in patients with #UlcerativeColitis. Read more here: https
RT @NMGastro: Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Stephen Hanauer, MD and colle…
Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Stephen Hanauer, MD and colleagues evaluate the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy. #Gastro ht
Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Stephen Hanauer, MD and colleagues evaluate the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy. #Gastro ht
Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colleagues evaluate the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy. #Gastro ht
RT @NMGastro: Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colle…
RT @NMGastro: Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colle…
More info. on the work of leading #IBD physician @NMH_SHanauerMD of @NorthwesternMed Digestive Health Center here: https://t.co/fJx2Wy6QFX @NUFeinbergMed @sciencedirect @pfizer #Tofacitinib #ResearchMatters
Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colleagues evaluate the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy. #Gastro ht
@YagoGlezLama @DCharabaty @EdwardLoftus2 @SchairerIBDMD @Iagorlago @IBDMD @ibdtweets @MRegueiroMD @IBD_FloMD @UofM_GI_Head @EdBarnesMD @ibdgijami @IBD_Afzali @FITWITMD @AmerGastroAssn Definitely possible. But in bionaive response times can be reasonably fa
RT @NMGastro: Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colle…
RT @NMGastro: Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colle…
Can Tofacitinib Induction Therapy help reduce the symptoms of patients with #UlcerativeColitis? Dr. Stephen Hanauer and colleagues evaluate the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy. #Gastro ht
RT @NMGastro: "Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis" lead by Dr. Stephen Hanau…
RT @NMGastro: "Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis" lead by Dr. Stephen Hanau…
"Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis" lead by Dr. Stephen Hanauer. @NMH_SHanauerMD #Gastroenterology #Gastro #UlcerativeColitis https://t.co/zPUDUhWEPq https://t.co/9tDQzEhWoA
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
RT @santigarcial: 3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado? https://t.co/xidLGuEmFJ
3 días!! ¿Podría ser Útil en el brote grave en paciente ingresado?
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
RT @WestKentGastro: Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improve…
Tofacitinib, an oral JAK inhibitor, in patients with moderate to severe ulcerative colitis led to a significant improvement in symptoms within 3 days of starting treatment. Early response predicted better outcomes at wk 8. Really exciting data @AGA_CGH htt
Hoping for a paradigm shift in #UC therapy after @NMH_SHanauerMD paper showing that in those who failed multiple therapies, #tofacitinib may be a good option for acute #UC. Right now not easily available in the hospital. https://t.co/JMbTYdQhps.
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
RT @aegastro: Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada…
Colitis ulcerosa moderada - grave que no responde a corticoides, IS - antiTNFalfa. Tofacitinib (inhibidor de JAK) 10 mg cada 12 horas oral puede ser una alternativa con respuesta rápida (3 dias). #aegastro https://t.co/h0XX3fqOwF
RT @NMGastro: In a recent publication, Dr. Stephen Hanauer & colleagues have concluded that in a post-hoc analysis of data from the phase 3…
RT @NMGastro: In a recent publication, Dr. Stephen Hanauer & colleagues have concluded that in a post-hoc analysis of data from the phase 3…
In a recent publication, Dr. Stephen Hanauer & colleagues have concluded that in a post-hoc analysis of data from the phase 3 trials of induction therapy, they found significant improvements in symptoms in 3 days by using #tofacitinib. @NMH_SHanauerMD
RT @VUMCibd: Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSI…
RT @VUMCibd: Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSI…
RT @VUMCibd: Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSI…
RT @VUMCibd: Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSI…
RT @VUMCibd: Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSI…
Tofacitinib can potentially improve #symptoms within #days in #UC @AGA_CGH #IBD https://t.co/NGtyLvb61D https://t.co/mPGesSILgA
RT @KTPARKMD: Post-hoc data for tofacitinib - a small molecule - support its faster mechanism of therapeutic action (within the first week…
RT @KTPARKMD: Post-hoc data for tofacitinib - a small molecule - support its faster mechanism of therapeutic action (within the first week…
RT @ibddoctor: Fast - is is fast enough to reduce steroid use? #IBD https://t.co/S2nCWfpKFJ
RT @ibddoctor: Fast - is is fast enough to reduce steroid use? #IBD https://t.co/S2nCWfpKFJ
Fast - is is fast enough to reduce steroid use? #IBD
Post-hoc data for tofacitinib - a small molecule - support its faster mechanism of therapeutic action (within the first week in some patients w colitis) than slower-onset biologics. https://t.co/Kj2jcE7dPZ